[{"source":"Faculté de droit Travaux récents","description":"dc.contributor.author: Gonzalez Fernandez, Nadia dc.date.issued: 2026-10 dc.description.abstract: La diversité logicielle contribue à améliorer la fiabilité et la sécurité des systèmes depuis les années 1960, notamment gr'ce à des modèles dans lesquels une autorité centrale mandate et certifie des implémentations indépendantes. Au cours de la dernière décennie, Ethereum a déployé la diversité à grande échelle sous une forme nouvelle : 11 clients indépendants y coexistent sans être mandatés ni certifiés par une autorité centrale, tout en bénéficiant de la diversité déjà présente dans l’écosystème open source. Cette thèse étudie Ethereum comme un exemple de ce modèle émergent de diversité logicielle, en examinant son adoption, son étendue dans le code des clients et les défis qu’elle soulève. Nous combinons des entretiens semi-directifs avec sept contributeurs impliqués dans le développement, la coordination et le suivi de la diversité des clients, avec la première analyse statique complète de la chaîne d’approvisionnement logicielle des 11 clients les plus utilisés. Deux principaux résultats se dégagent. Premièrement, la communauté Ethereum veille activement au maintien de cette diversité au moyen d’une spécification commune, d’un suivi continu de la distribution des clients, de financements dédiés et d’interventions visant à limiter leur concentration. Deuxièmement, notre analyse montre que cette diversité s’étend au code : huit moteurs de bases de données indépendants sont utilisés par les 11 clients, tandis que les équipes convergent volontairement vers les composants les plus difficiles à implémenter correctement et privilégient leur audit plutôt que la multiplication d’alternatives non vérifiées. Ainsi, Ethereum constitue un exemple de diversité logicielle étendue et activement entretenue par sa communauté.; Software diversity has improved reliability and security in systems since the 1960s, through models in which a central authority commissions and certifies independent implementations. Over the last decade, Ethereum has deployed diversity at scale in a new form: 11 independent clients coexist without any central authority commissioning or certifying them, while also leveraging the diversity already present in the open-source ecosystem. This thesis studies Ethereum as a case of this emerging software diversity model, asking how such diversity is adopted, how far it reaches into client code, and what challenges it introduces. We combine semi-structured interviews with seven contributors who build, coordinate, and monitor client diversity with the first comprehensive static analysis of the software supply chain of the 11 most widely used clients. Two results follow. First, the Ethereum community actively cares for and sustains its client diversity: interviewees describe coordination through a shared specification, continuous monitoring of client distribution, dedicated funding, and intervention against client concentration. For example, when Prysm exceeded 60% of the consensus layer, the community organized a campaign to redistribute validators away from it. Second, our supply chain analysis confirms that this diversity extends into the codebase: eight independent database engines back the 11 clients, and teams deliberately converge on the components hardest to implement correctly, funding their audit rather than multiplying unverified alternatives. Ethereum exhibits extensive software diversity that its community actively cares for and maintains. This sets an","id":3215934,"titre":"State of software diversity in ethereum","url":"https://hdl.handle.net/1866/46704","pubDate":"Wed, 14 Oct 2026 08:14:30 +0200"},{"source":"FTC USA Business Blog Posts","description":"First FTC ROSCA case challenges bogus BOGO and \"free\" claims wfg-adm109 October 21, 2014 | 12:02PM First FTC ROSCA case challenges bogus BOGO and \"free\" claims By Lesley Fair It’s called ROSCA – the Restore Online Shoppers’ Confidence Act – and it prohibits marketers from charging consumers for an online transaction unless the marketer has clearly disclosed all material terms of the deal and received the consumer’s express informed consent. Your e-commerce clients will want to know about the FTC’s first ROSCA case , filed recently in Nevada. According to the lawsuit, Health Formulas, LLC and a tangle of related California- and Nevada-based companies and individuals – consumers may know them as Simple Pure Nutrition – pitched a variety of products for weight loss, muscle building, virility, and skin care. The defendants advertised diet supplements like Pure Green Coffee Bean Plus and RKG Extreme as a shortcut to drop the pounds: “Burn fat without diet or exercise,” “Extreme weight loss!” “Shed pounds fast!” “Super concentrated double fat burning,” etc. Among the defendants’ more colorful business names: Weight Loss Dojo, Longhorn Marketing (sorry, Texas fans), Black Bull, and Unleash the Thunder. But unsubstantiated weight loss claims were just the start. The FTC says the defendants lured people in with bogus promises of a “free” trial or deceptive buy-one-get-one (BOGO) offers. Then they tricked consumers into giving their credit or debit card information with the false implication that consumers had to “just pay shipping.”   Digits in hand, the defendants really went to town, allegedly signing consumers up without their authorization for a negative option program that billed their accounts over and over again, to the monthly tune of between $60 and $210. The FTC says the defendants violated ROSCA by using a negative option feature without providing clear and conspicuous disclosures, getting the consumer’s express informed consent, and offering a simple mechanism for stopping the recurring charges. The FTC’s complaint also cites the defendants’ hard-to-find and hard-to-understand fine-print “terms and conditions,” which consumers could reach only by scrolling through the equivalent of two printed pages and clicking on an obscure hyperlink. Assuming they found it – and that’s a big if – the typical “terms and conditions” document was 10 pages long. On some websites, consumers had to scroll down the payment page to see further fine-print disclosures about the cost of the products. The first sentence reiterated what consumers generally understood (“You must pay a shipping and handling fee of $4.95 for us to send you a full 30 day supply of Garcinia Cambogia Extract”) but it wasn’t until the middle of the paragraph that the defendants mentioned that the trial period lasts only 14 days, that it began when the items were shipped (not delivered), and that consumers would be charged after that. Other websites didn’t even include that information. According to the lawsuit, consumers who attempted to take the defendants up on their money-back guarantee were met with a series of undisclosed roadblocks. In addition to the ROSCA counts, the FTC says the defendants’ practices violated the Electronic Fund Transfer Act by debiting consumers’ accounts on a recurring basis without their prior written authorization. What’s more, the complaint charges that the defendants continued to call people after being told to cut it out, in violation of the Telemarketing Sales Rule’s entity-specific Do Not Call provisions. The FTC says they also violated the TSR through a series of deceptive upsells. A federal judge has entered a temporary restraining order and the FTC is seeking to put a permanent stop to the defendants’ illegal practices. If your clients have ROSCA questions, the","id":3201052,"url":"https://www.ftc.gov/business-guidance/blog/2014/10/first-ftc-rosca-case-challenges-bogus-bogo-free-claims","titre":"First FTC ROSCA case challenges bogus BOGO and \"free\" claims","pubDate":"Wed, 07 Oct 2026 08:05:50 +0200"},{"titre":"FTC Challenges Anticompetitive Medical Device Deal","url":"https://www.ftc.gov/news-events/news/press-releases/2025/08/ftc-challenges-anticompetitive-medical-device-deal","pubDate":"Thu, 07 Aug 2025 09:48:21 +0200","description":"The Federal Trade Commission today moved to block medical device supplier Edwards Lifesciences Corp.’s (Edwards) proposed acquisition of JenaValve Technology, Inc. (JenaValve) due to concerns that the acquisition would limit patient access to lifesaving medical devices used to treat a potentially fatal heart condition. The FTC alleges that over the span of two days in July 2024, Edwards executed agreements to acquire both JenaValve and JC Medical, the two leading companies competing to bring to market transcatheter aortic valve replacement devices that treat a heart condition called aortic regurgitation (TAVR-AR devices). Edwards closed its acquisition of JC Medical in August 2024, and its proposed $945 million acquisition of JenaValve would combine the only two companies with ongoing clinical trials in the United States for a TAVR-AR device. The deal threatens to reduce competition in the TAVR-AR market, likely resulting in reduced innovation, diminished product quality, and potentially increased prices for consumers, according to the complaint. “ Edwards’ attempt to buy the U.S. market for TAVR-AR devices would eliminate the head-to-head competition that has spurred innovation for lifesaving artificial heart valves,” said Daniel Guarnera, Director of the FTC’s Bureau of Competition. “The FTC is taking action to stop this anticompetitive deal and ensure that JenaValve and Edwards’ JC Medical subsidiary continue competing to innovate, expand treatment eligibility, and keep down costs. Americans deserve all the benefits that come from competition between medical device makers, just as they do in other markets.” More than 8 million Americans suffer from aortic regurgitation, which occurs when the heart’s aortic valve does not close properly, causing blood to backflow into the heart. Currently, surgical valve replacement via open heart surgery is the only U.S. Food and Drug Administration (FDA) approved procedure to treat aortic regurgitation, and TAVR-AR devices offer a new and less invasive way to treat the condition. JenaValve is poised to become the first company to bring a TAVR-AR device, called Trilogy, to the commercial market in the United States. If Edwards acquires JenaValve, Edwards would gain control over the two most advanced TAVR-AR devices, the FTC complaint alleges. FDA approval or commercialization of any other TAVR-AR device in the United States by another company, aside from Edwards and JenaValve, is not expected for the foreseeable future. Direct head-to-head competition between Edwards, through its now-subsidiary JC Medical, and JenaValve has driven the two companies to accelerate the development of their TAVR-AR devices, the FTC’s complaint alleges. Ultimately, patients will benefit if JenaValve and Edwards continue to directly compete to complete their separate TAVR-AR device clinical trials, product improvements, and commercialization plans. The competition concerns caused by Edwards’ dual acquisition strategy are predicated on Edwards owning both JenaValve and JC Medical simultaneously, but Edwards has elected to attempt to buy JenaValve while retaining its ownership of JC Medical. Edwards has not been willing to engage on divesting JC Medical to resolve the competition concerns with the proposed JenaValve acquisition, according to the complaint. The Commission vote to issue an administrative complaint and authorize staff to seek a temporary restraining order and a preliminary injunction was 3-0. The federal court complaint and request for preliminary relief was filed in the U.S. District Court for the District of Columbia to halt the transaction pending an administrative proceeding. NOTE : The Commission issues an administrative complaint when it has “reason to believe” that the law has been or is being violated, and it appears to the Commission that a proceeding is in the public interest. The issuance of the administrative complaint marks the beginning of a proceeding in which the allegations will be tried in a formal","id":2298968,"source":"Federal Trade Commission Concurrence communiqués"},{"description":"Key Takeaways: Living Nightmare: A Mother’s Struggle with Toxic Mould Beverley McNally’s journey through the past five years has been marked by adversity and frustration as she battled against the insidious threat of toxic mould infiltrating her home. A devoted mother of two, Beverley faced unimaginable challenges as her family’s health and well-being were jeopardized by the relentless spread of mould. A Growing Menace: The Emergence of Toxic Mould What began as a minor leak in Beverley’s bathroom extractor fan burgeoned into a full-blown crisis, shrouding her Ealing townhouse in a veil of dampness and decay. As the mould crept The post The Shocking Reality: Mum’s Battle with Toxic Mould Reveals Landlord’s Negligence appeared first on Business Today","id":1228902,"source":"Business Today","url":"https://businesstoday.news/the-shocking-reality-mums-battle-with-toxic-mould-reveals-landlords-negligence/?utm_source=rss&utm_medium=rss&utm_campaign=the-shocking-reality-mums-battle-with-toxic-mould-reveals-landlords-negligence","titre":"The Shocking Reality: Mum’s Battle with Toxic Mould Reveals Landlord’s Negligence","pubDate":"Thu, 04 Apr 2024 16:35:47 +0200"}]